25m Health

25m Health is not a venture fund in the conventional sense, and founders who treat it as one will misread the engagement. It is the healthcare arm of 25madison, a Nashville-based startup studio operating as a joint venture with Lifepoint Health and capital backing tied to Apollo. The structure matters because it dictates how the firm sources, builds, and supports companies. 25m Health does not primarily wait for inbound pitch decks; it forms companies inside the studio, often around a thesis the team has refined with a health system partner, and then capitalizes them through pre-seed and seed rounds. For founders, that means the most productive conversations are usually with operators who want to be co-founders inside the studio rather than outside founders seeking a passive check.

The investment thesis is anchored in problems that present themselves inside large health systems and that are unlikely to be solved by horizontal software vendors. Lifepoint Health, with its substantial network of community hospitals and post-acute facilities, gives the studio a structured view of operational pain points across rural and community-based care delivery, and the studio uses that vantage to identify high-conviction wedges in digital health, Health IT, and tech-enabled services. The thesis tends to favor companies that can demonstrate value to a payer, provider, or employer customer within an identifiable budget line, rather than pure consumer-facing wellness plays. It also favors models that benefit from Lifepoint’s distribution from day one, giving studio companies a structural advantage on early commercial traction. The Apollo connection adds a credit and balance-sheet sophistication that informs how the studio thinks about capital intensity, asset-heavy services, and exit pathways.

Because portfolio company names are not enumerated in the source data, founders should ask the studio directly for a current roster during initial conversations. The pattern, however, is clear from the structure: companies that emerge from 25m Health tend to be tightly aligned with Lifepoint’s care delivery footprint, with go-to-market hypotheses that have been pressure-tested inside a real health system before incorporation. Founders evaluating the studio should expect that any company they help build will have a strong but specific commercial gravity around Lifepoint, and they should think carefully about how that initial dependency converts into broader market coverage over time.

Check sizes are not publicly disclosed, and the studio operates on terms that differ from a standard pre-seed round. Equity splits reflect the studio’s contribution of thesis development, recruiting, infrastructure, and the Lifepoint commercial relationship, which means founders typically retain less of the company than they would in a standard external pre-seed but enter with materially less risk on customer access and product-market fit. The stage focus is pre-seed and seed; later rounds are typically led by external investors as the company graduates from the studio. Founders should plan their cap table assuming that 25m Health will not be the lead at Series A, though it remains a meaningful holder and supporter.

Decision-making is centralized inside the small studio team in Nashville, working closely with Lifepoint counterparts on clinical and operational diligence. There is no broad partnership in the venture sense; the team functions more like a company-builder, and conviction tends to form through extended working sessions rather than a single pitch meeting. Founders who fit the model are usually identified through industry relationships, executive search, or repeat work with the studio rather than through cold inbound.

The right way to approach 25m Health is to lead with operating credentials in healthcare and a specific point of view on a problem that intersects Lifepoint’s network. Generic digital health pitches are unlikely to get traction. Warm introductions from Lifepoint executives, Nashville healthcare operators, or 25madison’s broader network materially increase the odds of a substantive conversation. Founders should be prepared to discuss not only what they would build but how they would build it inside a studio structure with shared governance.

What founders should know is that 25m Health offers a rare combination of pre-seed capital, distribution, and clinical validation through a real health system partner. The trade-off is structural: founders accept a different ownership profile and a tighter operating relationship than they would at a standard pre-seed. For operators who value de-risking customer access and clinical credibility above maximum founder equity, the model is unusually compelling. For founders who want full autonomy and a generic check, this is the wrong room.